230 related articles for article (PubMed ID: 1700997)
1. The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor.
Mold C; Walter EI; Medof ME
J Immunol; 1990 Dec; 145(11):3836-41. PubMed ID: 1700997
[TBL] [Abstract][Full Text] [Related]
2. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
Ito S; Tamura N; Fujita T
Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
[TBL] [Abstract][Full Text] [Related]
3. Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor.
Brodbeck WG; Liu D; Sperry J; Mold C; Medof ME
J Immunol; 1996 Apr; 156(7):2528-33. PubMed ID: 8786315
[TBL] [Abstract][Full Text] [Related]
4. Effect of gangliosides on activation of the alternative pathway of human complement.
Michalek MT; Bremer EG; Mold C
J Immunol; 1988 Mar; 140(5):1581-7. PubMed ID: 3346542
[TBL] [Abstract][Full Text] [Related]
5. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
Iwata K; Seya T; Ariga H; Nagasawa S
J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
[TBL] [Abstract][Full Text] [Related]
7. Alternative complement pathway-mediated myeloid cell cytotoxicity: repertoire of membrane factors participating in regulation of C3 deposition and cytolysis.
Matsumoto M; Sugita Y; Seya T
Eur J Immunol; 1991 Aug; 21(8):1787-92. PubMed ID: 1714391
[TBL] [Abstract][Full Text] [Related]
8. gp 58/68, a parasite component that contributes to the escape of the trypomastigote form of T. cruzi from damage by the human alternative complement pathway.
Fischer E; Ouaissi MA; Velge P; Cornette J; Kazatchkine MD
Immunology; 1988 Oct; 65(2):299-303. PubMed ID: 2973433
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a Trypanosoma cruzi C3 binding protein with functional and genetic similarities to the human complement regulatory protein, decay-accelerating factor.
Norris KA; Bradt B; Cooper NR; So M
J Immunol; 1991 Oct; 147(7):2240-7. PubMed ID: 1717552
[TBL] [Abstract][Full Text] [Related]
10. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
[TBL] [Abstract][Full Text] [Related]
11. Murine membrane inhibitor of complement which accelerates decay of human C3 convertase.
Kameyoshi Y; Matsushita M; Okada H
Immunology; 1989 Dec; 68(4):439-44. PubMed ID: 2481641
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
Medof ME; Kinoshita T; Nussenzweig V
J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
[TBL] [Abstract][Full Text] [Related]
13. Additional forms of human decay-accelerating factor (DAF).
Seya T; Farries T; Nickells M; Atkinson JP
J Immunol; 1987 Aug; 139(4):1260-7. PubMed ID: 2440950
[TBL] [Abstract][Full Text] [Related]
14. Complement activation induces the expression of decay-accelerating factor on human mesangial cells.
Shibata T; Cosio FG; Birmingham DJ
J Immunol; 1991 Dec; 147(11):3901-8. PubMed ID: 1719094
[TBL] [Abstract][Full Text] [Related]
15. Endogenous association of decay-accelerating factor (DAF) with C4b and C3b on cell membranes.
Kinoshita T; Medof ME; Nussenzweig V
J Immunol; 1986 May; 136(9):3390-5. PubMed ID: 2420889
[TBL] [Abstract][Full Text] [Related]
16. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase.
Moore FD; Austen KF; Fearon DT
J Immunol; 1982 Mar; 128(3):1302-6. PubMed ID: 6915957
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
Sahu A; Kay BK; Lambris JD
J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
[TBL] [Abstract][Full Text] [Related]
18. Host-specific evasion of the alternative complement pathway by schistosomes correlates with the presence of a phospholipase C-sensitive surface molecule resembling human decay accelerating factor.
Pearce EJ; Hall BF; Sher A
J Immunol; 1990 Apr; 144(7):2751-6. PubMed ID: 1690776
[TBL] [Abstract][Full Text] [Related]
19. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme.
Kinoshita T; Takata Y; Kozono H; Takeda J; Hong KS; Inoue K
J Immunol; 1988 Dec; 141(11):3895-901. PubMed ID: 3183384
[TBL] [Abstract][Full Text] [Related]
20. Purification and characterization of decay-accelerating factor (DAF) from Raji cells.
Fujita T; Shinkai Y; Inoue T; Tamura N
Immunology; 1988 Jul; 64(3):369-74. PubMed ID: 2457546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
